BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021
Shots:
- The ongoing P-IIb POC- open-label study involves assessing Encaleret (starting dose: 30 mg) in 6 patients for the treatment of ADH1
- The results showed normalization of blood calcium and urine calcium- well-tolerated and consistent mineral responses with no serious AEs- and no AEs of moderate or severe intensity reported after 5 days- at doses up to 180 mg
- Encaleret could be the 1st approved therapy option indicated specifically for the treatment of ADH1- if the development program is successful
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com